Literature DB >> 16353344

Paraoxonase (PON1): from toxicology to cardiovascular medicine.

Lucio G Costa1, Toby B Cole, Clement E Furlong.   

Abstract

Paraoxonase (PON1) is a liver and plasma enzyme most studied because of its ability to hydrolyze the active metabolites of several organophosphorus insecticides. The discovery that PON1 can also metabolize oxidized phospholipids has spurred research on its possible role in coronary heart disease and atherosclerosis. Additionally, its potential roles in metabolizing pharmaceutical drugs and microbial quorum sensing factors are also being explored. PON1 displays several polymorphisms that influence both its level of expression and its catalytic activity, thus determining the rates at which a given individual will detoxify a specific insecticide, metabolize harmful oxidized lipids, and activate or inactivate specific drugs and quorum sensing factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353344

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  10 in total

1.  Regulation of paraoxonase 1 (PON1) in PCB 126-exposed male Sprague Dawley rats.

Authors:  Hua Shen; Larry W Robertson; Gabriele Ludewig
Journal:  Toxicol Lett       Date:  2012-01-12       Impact factor: 4.372

2.  Methylmercury exposure, PON1 gene variants and serum paraoxonase activity in Eastern James Bay Cree adults.

Authors:  Olivia Drescher; Eric Dewailly; Caroline Diorio; Nathalie Ouellet; Elhadji Anassour Laouan Sidi; Belkacem Abdous; Beatriz Valera; Pierre Ayotte
Journal:  J Expo Sci Environ Epidemiol       Date:  2014-01-22       Impact factor: 5.563

Review 3.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

4.  Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses.

Authors:  Michael Maes; Kamila Landucci Bonifacio; Nayara Rampazzo Morelli; Heber Odebrecht Vargas; Estefânia Gastaldello Moreira; Drozdstoy St Stoyanov; Décio Sabbatini Barbosa; André F Carvalho; Sandra Odebrecht Vargas Nunes
Journal:  Neurotox Res       Date:  2018-05-07       Impact factor: 3.911

5.  Evidence for the presence of active paraoxonase 1 in small-dense low-density lipoprotein.

Authors:  Alejandro Gugliucci; Russell Caccavello; Kazuhiko Kotani; Satoshi Kimura
Journal:  Redox Rep       Date:  2014-02-14       Impact factor: 4.412

Review 6.  Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

Authors:  Lucio G Costa; Gennaro Giordano; Toby B Cole; Judit Marsillach; Clement E Furlong
Journal:  Toxicology       Date:  2012-07-31       Impact factor: 4.221

7.  Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

8.  Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes.

Authors:  Philip W Connelly; Bernard Zinman; Graham F Maguire; Mary Mamakeesick; Stewart B Harris; Robert A Hegele; Ravi Retnakaran; Anthony J G Hanley
Journal:  J Lipid Res       Date:  2009-01-18       Impact factor: 5.922

9.  Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene.

Authors:  Muhammad Idrees; Abdul Rauf Siddiq; Muhammad Ajmal; Muhammad Akram; Rana Rehan Khalid; Alamdar Hussain; Raheel Qamar; Habib Bokhari
Journal:  Genet Mol Biol       Date:  2018-07-23       Impact factor: 1.771

Review 10.  Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?

Authors:  Estefania Gastaldello Moreira; Karine Maria Boll; Dalmo Guilherme Correia; Janaina Favaro Soares; Camila Rigobello; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.